phrykt

Travere Therapeutics, Inc. (TVTX): who owns it and who trades it

As of Nov 16, 2026, TVTX insiders reported 111 open-market sales worth $109M and no purchases in the last 12 months, with 99% of the sale value made under pre-set 10b5-1 plans. The largest seller was Eric M Dube (CEO), with $50.8M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Travere Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TVTX

317 funds and institutions reported TVTX shares worth $6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Jupiter Topco LLC with 12.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Jupiter Topco LLC12.2%
BlackRock, Inc.8.6%
FMR LLC (Fidelity)7.6%
Bank of America Corp4.9%
State Street Corp4.6%
Vanguard Capital Management LLC4.4%
Perceptive Advisors LLC4.0%
Nomura Asset Management International Inc.3.0%
Adage Capital Partners Gp, L.l.c.2.8%
Geode Capital Management, LLC2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Jupiter Topco LLC11.32M12.18%$643M–
BlackRock, Inc.8.02M8.63%$456M+3%
FMR LLC (Fidelity)7.10M7.63%$403M-35%
Bank of America Corp4.57M4.91%$260M+240%
State Street Corp4.26M4.58%$242M-14%
Vanguard Capital Management LLC4.11M4.42%$233M+2%
Perceptive Advisors LLC3.75M4.04%$213M-9%
Nomura Asset Management International Inc.2.81M3.02%$160M-14%
Adage Capital Partners Gp, L.l.c.2.57M2.76%$146M+163%
Geode Capital Management, LLC2.37M2.55%$135M+0%
Rock Springs Capital Management LP2.18M2.34%$124M+47%
Kynam Capital Management, LP2.00M2.15%$114M+27%
Stephens Investment Management Group LLC1.88M2.02%$107M+4%
Renaissance Technologies LLC1.83M1.97%$104M-7%
Emerald Advisers, LLC1.60M1.72%$90.9M+3%
Armistice Capital, LLC1.57M1.69%$89.3M-68%
Two Sigma Investments, LP1.57M1.68%$88.9M+4%
Vanguard Portfolio Management LLC1.54M1.66%$87.6M-10%
Goldman Sachs Group Inc1.54M1.65%$87.2M-11%
Wellington Management Group LLP1.53M1.65%$87.1M+50%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TVTX insiders reported $0 of open-market purchases and $109M of sales. 99% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$109M
111 trades, 11 people
Sales under a 10b5-1 plan
99%
Share of sale value
Latest trade
Oct 15, 2026
Filed Oct 19, 2026

Purchases and sales by month

$66.3M$66.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 15, 2026Eric M DubeCEOSale plan128,065$52.97$6.8MForm 4
Oct 15, 2026Eric M DubeCEOSale plan37,270$54.20$2MForm 4
Oct 15, 2026Eric M DubeCEOSale plan78,400$55.02$4.3MForm 4
Sep 17, 2026Peter HeermaVice presidentSale plan8,282$65.07$539KForm 4
Sep 17, 2026Eric M DubeCEOSale plan6,802$64.95$442KForm 4
Sep 17, 2026Eric M DubeCEOSale plan101,691$64.59$6.6MForm 4
Sep 16, 2026William E. RoteChief Research OfficerSale plan65,104$63.12$4.1MForm 4
Sep 16, 2026William E. RoteChief Research OfficerSale plan47,746$63.61$3MForm 4
Sep 16, 2026Peter HeermaVice presidentSale plan93,604$63.25$5.9MForm 4
Sep 16, 2026Peter HeermaVice presidentSale plan79,113$63.65$5MForm 4
Sep 16, 2026Eric M DubeCEOSale plan99,716$63.26$6.3MForm 4
Sep 16, 2026Eric M DubeCEOSale plan96,125$63.64$6.1MForm 4
Sep 15, 2026William E. RoteChief Research OfficerSale plan63,907$61.99$4MForm 4
Sep 15, 2026William E. RoteChief Research OfficerSale plan29,021$62.66$1.8MForm 4
Sep 15, 2026William E. RoteChief Research OfficerSale plan3,000$63.65$191KForm 4
Sep 15, 2026William E. RoteChief Research OfficerSale plan270$65.31$17.6KForm 4
Sep 15, 2026Peter HeermaVice presidentSale plan1,431$65.31$93.5KForm 4
Sep 15, 2026Peter HeermaVice presidentSale plan1,400$63.65$89.1KForm 4
Sep 15, 2026Peter HeermaVice presidentSale plan27,421$62.59$1.7MForm 4
Sep 15, 2026Peter HeermaVice presidentSale plan71,938$62.05$4.5MForm 4
Sep 15, 2026Jula InrigVice presidentSale plan25,390$62.02$1.6MForm 4
Sep 15, 2026Jula InrigVice presidentSale plan400$65.31$26.1KForm 4
Sep 15, 2026Jula InrigVice presidentSale plan1,600$63.69$102KForm 4
Sep 15, 2026Jula InrigVice presidentSale plan17,284$62.62$1.1MForm 4
Sep 15, 2026Elizabeth E ReedChief Legal Officer and Sale plan1,400$63.69$89.2KForm 4
Sep 15, 2026Elizabeth E ReedChief Legal Officer and Sale plan300$65.31$19.6KForm 4
Sep 15, 2026Elizabeth E ReedChief Legal Officer and Sale plan13,874$62.63$869KForm 4
Sep 15, 2026Elizabeth E ReedChief Legal Officer and Sale plan21,926$62.03$1.4MForm 4
Sep 15, 2026Eric M DubeCEOSale plan63,498$61.99$3.9MForm 4
Sep 15, 2026Eric M DubeCEOSale plan28,796$62.66$1.8MForm 4
Sep 15, 2026Eric M DubeCEOSale plan3,102$63.64$197KForm 4
Sep 15, 2026Christopher R. ClineCFOSale plan27,473$62.00$1.7MForm 4
Sep 15, 2026Christopher R. ClineCFOSale plan20,735$62.61$1.3MForm 4
Sep 15, 2026Christopher R. ClineCFOSale plan1,900$63.69$121KForm 4
Sep 15, 2026Sandra CalvinVice presidentSale plan300$63.66$19.1KForm 4
Sep 15, 2026Sandra CalvinVice presidentSale plan4,275$62.14$266KForm 4
Sep 15, 2026Sandra CalvinVice presidentSale plan800$62.85$50.3KForm 4
Sep 10, 2026Jeffrey A MecklerDirectorSale plan3,100$68.09$211KForm 4
Sep 10, 2026Jeffrey A MecklerDirectorSale plan14,000$67.46$944KForm 4
Sep 10, 2026Jeffrey A MecklerDirectorSale plan1,200$66.15$79.4KForm 4
Sep 10, 2026Jeffrey A MecklerDirectorSale plan1,700$65.39$111KForm 4
Sep 2, 2026Christopher R. ClineCFOSale642$66.37$42.6KForm 4
Aug 18, 2026Gary A LyonsDirectorSale plan900$63.86$57.5KForm 4
Aug 18, 2026Gary A LyonsDirectorSale plan4,100$63.27$259KForm 4
Aug 17, 2026Gary A LyonsDirectorSale plan1,900$62.53$119KForm 4
Aug 17, 2026Gary A LyonsDirectorSale plan2,600$63.50$165KForm 4
Aug 17, 2026Gary A LyonsDirectorSale plan500$64.16$32.1KForm 4
Jun 12, 2026Timothy CoughlinDirectorSale plan10,000$50.07$501KForm 4
Jun 12, 2026Roy D. BaynesDirectorSale plan4,500$50.00$225KForm 4
May 15, 2026Timothy CoughlinDirectorSale plan3,250$43.49$141KForm 4
May 6, 2026William E. RoteChief Research OfficerSale plan2,763$43.95$121KForm 4
May 6, 2026Elizabeth E ReedChief Legal Officer and Sale plan2,076$43.95$91.2KForm 4
May 6, 2026Jula InrigCHIEF MEDICAL OFFICERSale plan311$43.95$13.7KForm 4
May 6, 2026Eric M DubeCEOSale plan22,500$43.95$989KForm 4
May 6, 2026Christopher R. ClineCFOSale plan310$43.95$13.6KForm 4
May 5, 2026Roy D. BaynesDirectorSale plan4,500$46.65$210KForm 4
May 5, 2026Elizabeth E ReedChief Legal Officer and Sale plan2,174$46.65$101KForm 4
May 5, 2026Christopher R. ClineCFOSale plan2,181$46.65$102KForm 4
May 4, 2026Jeffrey A MecklerDirectorSale plan8,000$45.00$360KForm 4
May 4, 2026Elizabeth E ReedChief Legal Officer and Sale plan20,000$45.00$900KForm 4
May 1, 2026Roy D. BaynesDirectorSale plan9,750$44.22$431KForm 4
Apr 22, 2026William E. RoteChief Research OfficerSale plan9,100$39.09$356KForm 4
Apr 15, 2026Eric M DubeCEOSale plan56,815$41.01$2.3MForm 4
Apr 15, 2026Eric M DubeCEOSale plan20$42.66$853Form 4
Apr 15, 2026Eric M DubeCEOSale plan7,165$41.75$299KForm 4
Apr 15, 2026Elizabeth E ReedChief Legal Officer and Sale plan1,559$42.53$66.3KForm 4
Apr 15, 2026Elizabeth E ReedChief Legal Officer and Sale plan5,226$41.62$218KForm 4
Apr 15, 2026Christopher R. ClineCFOSale plan1,014$42.61$43.2KForm 4
Apr 15, 2026Jula InrigCHIEF MEDICAL OFFICERSale plan1,018$42.61$43.4KForm 4
Apr 14, 2026Gary A LyonsDirectorSale plan8,000$41.07$329KForm 4
Apr 14, 2026Roy D. BaynesDirectorSale plan26,000$41.07$1.1MForm 4
Apr 14, 2026Roy D. BaynesDirectorSale plan6,750$42.12$284KForm 4
Apr 14, 2026Sandra CalvinVice presidentSale plan21,977$41.07$903KForm 4
Apr 14, 2026Peter HeermaCHIEF COMMERCIAL OFFICERSale7,215$41.93$303KForm 4
Apr 14, 2026Elizabeth E ReedChief Legal Officer and Sale plan37,500$41.07$1.5MForm 4
Apr 14, 2026Christopher R. ClineCFOSale plan7,239$41.93$304KForm 4
Apr 14, 2026Christopher R. ClineCFOSale plan9$41.07$370Form 4
Apr 13, 2026Christopher R. ClineCFOSale plan65$28.85$1.9KForm 4
Apr 6, 2026Roy D. BaynesDirectorSale plan10,000$33.00$330KForm 4
Apr 1, 2026Eric M DubeCEOSale plan25,098$31.46$790KForm 4
Apr 1, 2026Eric M DubeCEOSale plan34,902$30.55$1.1MForm 4
Apr 1, 2026Elizabeth E ReedChief Legal Officer and Sale plan10,000$30.00$300KForm 4
Mar 16, 2026Elizabeth E ReedChief Legal Officer and Sale plan10,000$28.09$281KForm 4
Feb 20, 2026Eric M DubeCEOSale plan60,000$30.10$1.8MForm 4
Feb 17, 2026Elizabeth E ReedChief Legal Officer and Sale plan4,321$28.26$122KForm 4
Feb 17, 2026Elizabeth E ReedChief Legal Officer and Sale plan5,679$27.50$156KForm 4
Feb 4, 2026Elizabeth E ReedChief Legal Officer and Sale plan509$32.74$16.7KForm 4
Feb 4, 2026Elizabeth E ReedChief Legal Officer and Sale plan2,485$32.07$79.7KForm 4
Feb 4, 2026Jula InrigCHIEF MEDICAL OFFICERSale plan232$32.85$7.6KForm 4
Feb 4, 2026Jula InrigCHIEF MEDICAL OFFICERSale plan1,547$32.11$49.7KForm 4
Feb 4, 2026Christopher R. ClineCFOSale plan110$32.90$3.6KForm 4
Feb 4, 2026Christopher R. ClineCFOSale plan1,635$32.14$52.5KForm 4
Feb 3, 2026Eric M DubeCEOSale plan33,635$32.70$1.1MForm 4
Feb 3, 2026Eric M DubeCEOSale plan66,452$32.06$2.1MForm 4
Feb 3, 2026Jula InrigCHIEF MEDICAL OFFICERSale6,956$32.12$223KForm 4
Feb 3, 2026Christopher R. ClineCFOSale7,242$32.12$233KForm 4
Feb 3, 2026Peter HeermaCHIEF COMMERCIAL OFFICERSale7,310$32.12$235KForm 4
Feb 3, 2026William E. RoteChief Research OfficerSale plan12,446$32.87$409KForm 4
Feb 3, 2026Elizabeth E ReedChief Legal Officer and Sale7,175$32.12$230KForm 4
Feb 3, 2026Sandra CalvinVice presidentSale4,333$32.12$139KForm 4

Latest 100 of 111 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Eric M DubeCHIEF EXECUTIVE OFFICER, Director–$50.8MOct 15, 2026
Peter HeermaCHIEF COMMERCIAL OFFICER–$18.6MSep 17, 2026
William E. RoteChief Research Officer–$16.4MSep 16, 2026
Elizabeth E ReedChief Legal Officer and GC–$6.7MSep 15, 2026
Christopher R. ClineCHIEF FINANCIAL OFFICER–$4.6MSep 15, 2026
Jula InrigCHIEF MEDICAL OFFICER–$3.9MSep 15, 2026
Roy D. BaynesDirector–$2.5MJun 12, 2026
Sandra CalvinSVP, CHIEF ACCOUNTING OFFICER–$1.8MSep 15, 2026
Jeffrey A MecklerDirector–$1.7MSep 10, 2026
Gary A LyonsDirector–$961KAug 18, 2026
Timothy CoughlinDirector–$642KJun 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TVTX short interest

Moderate short interest. 10.0% of TVTX shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 32%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.56M TVTX shares were sold short, 10.0% of the shares outstanding, down 12.4% from the report before. At the average daily volume of 2.02M shares, buying them all back would take about 4.7 trading days (days to cover).

Shares short, % of all shares

9.96%May 15Oct 3016.0%

Days to cover

4.7May 15Oct 3011.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.56M9.96%-12%2.02M4.7
Oct 15, 202610.91M11.58%-14%2.08M5.2
Sep 30, 202612.66M13.43%-2%1.75M7.2
Sep 15, 202612.96M13.74%+8%1.25M10.4
Aug 31, 202612.00M12.74%+1%1.26M9.6
Aug 14, 202611.94M12.67%+2%2.10M5.7
Jul 31, 202611.68M12.39%-3%1.24M9.4
Jul 15, 202612.02M12.92%-5%1.31M9.2
Jun 30, 202612.69M13.64%-6%2.69M4.7
Jun 15, 202613.44M14.45%-5%2.10M6.4
May 29, 202614.12M15.19%+1%1.73M8.2
May 15, 202614.01M15.06%-1%3.13M4.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Travere Therapeutics company events

Travere Therapeutics filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026ResultsReleased financial results. Filing
  2. Sep 21, 2026LeadershipTravere Therapeutics, Inc. and Eric Dube, Ph.D., mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position as the Company’s President and Chief Executive Officer and as a member of the Board of Directors of the Company effective… Filing
  3. Aug 4, 2026ResultsReleased financial results. Filing
  4. Jul 9, 2026LeadershipSandra Calvin, chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, provided notice to the Company of her intention to retire from employment with the Company following the filing of the Company’s Annual Report on Form 10-K expected in February 2027. Filing
  5. Jun 16, 2026LeadershipWilliam Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027, the 10 year anniversary of his employment with the Company. Filing
  6. Jun 2, 2026AgreementTravere Therapeutics, Inc. entered into a license and collaboration agreement with Everest Medicines (Singapore) Pte. Filing
  7. May 21, 2026LeadershipAs discussed below in Item 5.07, Travere Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders at which the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by… Filing
  8. May 11, 2026AgreementTravere Therapeutics, Inc. completed its registered underwritten public offering of $525.0 million of 0.50% Convertible Senior Notes due 2032 (such notes, the “Notes,” and such offering, the “Offering”) pursuant to the underwriting agreement with J.P. Morgan Securities LLC, Jefferies LLC and… Filing
  9. May 4, 2026ResultsReleased financial results. Filing
  10. Apr 14, 2026AnnouncementTravere Therapeutics, Inc. announced that the U.S. Food and Drug Administration has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis without nephrotic syndrome. Filing
  11. Feb 19, 2026ResultsReleased financial results. Filing
  12. Jan 13, 2026AnnouncementTravere Therapeutics, Inc. announced that the U.S. Food and Drug Administration has extended the review timeline of its supplemental New Drug Application for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis. Filing
  13. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Travere Therapeutics financials

Famous investors that hold TVTX

5 of the 50 well-known investors we track reported holding TVTX in their latest 13F filing. The largest position is Jim Simons's, worth $63.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.08M$63.5M0.1%-41%
Steve Cohen · Point72 Asset ManagementQ3 2026441,372$26M0.0%-8%
Ken Griffin · Citadel AdvisorsQ3 202666,271$3.9M0.0%+72%
Ken Fisher · Fisher Asset ManagementQ3 202614,247$839K0.0%-10%
Israel Englander · Millennium ManagementQ3 20268,116$478K0.0%-90%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named TVTX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BANK OF AMERICA CORP /DE/13G/A7.1%
Nov 16, 2026BANK OF AMERICA CORP /DE/13G/A7.1%
Nov 5, 2026FMR LLC13G/A6.1%
Nov 5, 2026FMR LLC13G/A6.1%

Questions about Travere Therapeutics, Inc. (TVTX) stock

Who owns the most TVTX stock?

The largest reported owner of Travere Therapeutics, Inc. (TVTX) is Jupiter Topco LLC, with 12.2% of the company. In total, 317 funds and institutions reported holding TVTX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are TVTX insiders buying or selling?

In the last 12 months, TVTX insiders reported no open-market purchases and 111 sales worth $109M. The latest trade was on Oct 15, 2026. See every trade.

What is the short interest in TVTX?

As of Oct 30, 2026, 9.56M TVTX shares were sold short, 10.0% of the shares outstanding, down 12.4% from the report before. At the average daily volume of 2.02M shares, buying them all back would take about 4.7 trading days (days to cover). See the history.

Which famous investors hold TVTX?

5 of the 50 well-known investors we track reported TVTX in their latest 13F filing, including Jim Simons, Steve Cohen, Ken Griffin. The largest position is worth $63.5M. See all holders.

Executive pay

Travere Therapeutics's chief executive was paid a total of $8.5M for the year ended Dec 31, 2025, up 62% from $5.2M the year before. In the last 12 months, Travere Therapeutics's executives and directors bought no stock on the open market and sold $109M.

Chief executive, total pay$8.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$24.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.